Jorge Duconge to Aryldialkylphosphatase
This is a "connection" page, showing publications Jorge Duconge has written about Aryldialkylphosphatase.
Connection Strength
1.617
-
Monero-Paredes M, Santiago E, Carrasquillo-Carrion K, Renta JY, Rogozin IB, Roche-Lima A, Duconge J. Paraoxonase-1 as a Cardiovascular Biomarker in Caribbean Hispanic Patients Treated with Clopidogrel: Abundance and Functionality. Int J Mol Sci. 2024 Oct 03; 25(19).
Score: 0.877
-
Hernandez-Suarez DF, Tomassini-Fernandini JC, Cuevas A, Rosario-Berrios AN, Nu?ez-Medina HJ, Padilla-Arroyo D, Rivera N, Liriano J, Vega-Roman RK, Renta JY, Melin K, Duconge J. Clinical Relevant Polymorphisms Affecting Clopidogrel Pharmacokinetics and Pharmacodynamics: Insights from the Puerto Rico Newborn Screening Program. Int J Environ Res Public Health. 2018 05 30; 15(6).
Score: 0.565
-
Hernandez-Suarez DF, N??ez-Medina H, Scott SA, Lopez-Candales A, Wiley JM, Garcia MJ, Melin K, Nieves-Borrero K, Rodriguez-Ruiz C, Marshall L, Duconge J. Effect of cilostazol on platelet reactivity among patients with peripheral artery disease on clopidogrel therapy. Drug Metab Pers Ther. 2018 03 28; 33(1):49-55.
Score: 0.139
-
Melin K, Moon JY, Qi Q, Hernandez-Suarez DF, Duconge J, Hua S, Gonzalez S, Zeng D, Kaplan RC. Prevalence of pharmacogenomic variants affecting the efficacy of clopidogrel therapy in the Hispanic Community Health Study/Study of Latinos cohort. Pharmacogenomics. 2019 01; 20(2):75-83.
Score: 0.037